{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T09:04:43Z","timestamp":1766653483669,"version":"3.48.0"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The identification of genetic markers that will enable accurate diagnosis and prediction of the therapy outcome is a crucial step in managing rheumatologic and autoimmune diseases. Low-dose methotrexate is a mainstay therapeutic agent for treatment. The objective of this review is to summarize the data on candidate single nucleotide polymorphisms in methylenetetrahydrofolate reductase (\n                    <jats:italic>MTHFR<\/jats:italic>\n                    ) and solute carrier family 19 member 1 (\n                    <jats:italic>SLC19A1<\/jats:italic>\n                    ) genes involved in methotrexate pathways. Over the past decade, several functional polymorphisms affecting methylenetetrahydrofolate reductase activity have been studied in the context of low-dose methotrexate therapy. The most frequently investigated polymorphisms are rs1801133 (c.665C&gt;T) and rs1801131 (c.1286A&gt;C) in\n                    <jats:italic>MTHFR<\/jats:italic>\n                    gene and rs1051266 (c.80A&gt;G) in\n                    <jats:italic>SLC19A1<\/jats:italic>\n                    gene. Although the effects of these polymorphisms are remaining unclear, several studies have shown association with adverse effect while fewer studies have demonstrated association with remission or positive response to methotrexate. However, there is scarcity research in Latin American population assessing the influence of genetic variants in the pharmacokinetics and pharmacodynamics of methotrexate in the context of interethnic admixture. There is an urgent need of to expand these studies and to support the development of clinical pharmacogenomics guidelines.\n                  <\/jats:p>","DOI":"10.1515\/dmpt-2025-0047","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:10:21Z","timestamp":1763557821000},"page":"217-221","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenetic insights into\n                    <i>MTHFR<\/i>\n                    and\n                    <i>SLC19A1<\/i>\n                    variants in low-dose methotrexate therapy for rheumatologic diseases"],"prefix":"10.1515","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6679-1410","authenticated-orcid":false,"given":"Goitybell","family":"Mart\u00ednez T\u00e9llez","sequence":"first","affiliation":[{"name":"National Center of Medical Genetic, University of Medical Scienc e, Playa , La Havana , Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6009-0405","authenticated-orcid":false,"given":"Beatriz Marcheco","family":"Teruel","sequence":"additional","affiliation":[{"name":"National Center of Medical Genetic, University of Medical Scienc e, Playa , La Havana , Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025122507573873958_j_dmpt-2025-0047_ref_001","doi-asserted-by":"crossref","unstructured":"Chi, X, Huang, M, Tu, H, Zhang, B, Lin, X, Xu, H, et al.. Innate and adaptive immune abnormalities underlying autoimmune diseases: the genetic connections. Sci China Life Sci 2023;66:1\u201336. https:\/\/doi.org\/10.1007\/s11427-021-2187-3.","DOI":"10.1007\/s11427-021-2187-3"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_002","doi-asserted-by":"crossref","unstructured":"Mikhaylenko, DS, Nemtsova, MV, Bure, IV, Kuznetsova, EB, Alekseeva, EA, Tarasov, VV, et al.. Genetic polymorphisms associated with rheumatoid arthritis development and antirheumatic therapy response. Int J Mol Sci 2020;21:1\u201317. https:\/\/doi.org\/10.3390\/ijms21144911.","DOI":"10.3390\/ijms21144911"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_003","doi-asserted-by":"crossref","unstructured":"Karami, J, Aslani, S, Jamshidi, A, Garshasbi, M, Mahmoudi, M. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene 2019;702:8\u201316. https:\/\/doi.org\/10.1016\/j.gene.2019.03.033.","DOI":"10.1016\/j.gene.2019.03.033"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_004","doi-asserted-by":"crossref","unstructured":"Bedoui, Y, Guillot, X, S\u00e9lambarom, J, Guiraud, P, Giry, C, Jaffar-Bandjee, MC, et al.. Methotrexate an old drug with new tricks. Int J Mol Sci 2019;20:5023. https:\/\/doi.org\/10.3390\/ijms20205023.","DOI":"10.3390\/ijms20205023"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_005","doi-asserted-by":"crossref","unstructured":"Cronstein, BN, Aune, TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020;16:145\u201354. https:\/\/doi.org\/10.1038\/s41584-020-0373-9.","DOI":"10.1038\/s41584-020-0373-9"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_006","doi-asserted-by":"crossref","unstructured":"Lima, A, Monteiro, J, Bernardes, M, Sousa, H, Azevedo, R, Seabra, V, et al.. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. BioMed Res Int 2014;2014:1\u201311. https:\/\/doi.org\/10.1155\/2014\/368681.","DOI":"10.1155\/2014\/368681"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_007","doi-asserted-by":"crossref","unstructured":"Hiraoka, M, Kagawa, Y. Genetic polymorphisms and folate status. Congenital Anom 2017;57:142\u20139. https:\/\/doi.org\/10.1111\/cga.12232.","DOI":"10.1111\/cga.12232"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_008","doi-asserted-by":"crossref","unstructured":"Copped\u00e8, F, Stoccoro, A, Tannorella, P, Gallo, R, Nicol\u00ec, V, Migliore, L. Association of polymorphisms in genes involved in one-carbon metabolism with MTHFR methyla tion levels. Int J Mol Sci 2019;20:3754. https:\/\/doi.org\/10.3390\/ijms20153754.","DOI":"10.3390\/ijms20153754"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_009","doi-asserted-by":"crossref","unstructured":"\u0106alasan, MB, van den Bosch, OF, Creemers, MC, Custers, M, Heurkens, AH, van Woerkom, J, et al.. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 2013;15:1\u20135. https:\/\/doi.org\/10.1186\/ar4413.","DOI":"10.1186\/ar4413"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_010","doi-asserted-by":"crossref","unstructured":"Dupont-Lucas, C, Grandjean-Blanchet, C, Leduc, B, Tripcovici, M, Larocque, C, Gervais, F, et al.. Prevalence and risk factors for symptoms of methotrexate intolerance in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2017;23:298\u2013303. https:\/\/doi.org\/10.1097\/mib.0000000000001014.","DOI":"10.1097\/MIB.0000000000001014"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_011","doi-asserted-by":"crossref","unstructured":"Mehta, RS, Taylor, ZL, Martin, LJ, Rosen, MJ, Ramsey, LB. SLCO1B1 *15 allele is associated with methotrexate-induced nausea in pediatric patients with inflammatory bowel disease. Clin Transl Sci 2022;15:63\u20139. https:\/\/doi.org\/10.1111\/cts.13130.","DOI":"10.1111\/cts.13130"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_012","doi-asserted-by":"crossref","unstructured":"Kyvsgaard, N, Mikkelsen, TS, Als, TD, Christensen, AE, Corydon, TJ, Herlin, T. Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2021;19:51. https:\/\/doi.org\/10.1186\/s12969-021-00539-9.","DOI":"10.1186\/s12969-021-00539-9"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_013","doi-asserted-by":"crossref","unstructured":"Viatte, S, Barton, A. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol 2017;39:395\u2013408. https:\/\/doi.org\/10.1007\/s00281-017-0630-4.","DOI":"10.1007\/s00281-017-0630-4"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_014","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, G, Feist, E, Martiatu, M, Garay, H, Torres, B. Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in Cuban patients with early rheumatoid arthritis. Rheumatol Int 2020;40:1873\u201381. https:\/\/doi.org\/10.1007\/s00296-020-04580-x.","DOI":"10.1007\/s00296-020-04580-x"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_015","doi-asserted-by":"crossref","unstructured":"Yu, J, Zhou, P. The advances of methotrexate resistance in rheumatoid arthritis. Inflammopharmacology 2020:1\u201311. https:\/\/doi.org\/10.1007\/s10787-020-00741-3.","DOI":"10.1007\/s10787-020-00741-3"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_016","doi-asserted-by":"crossref","unstructured":"Rozen, R. Annotation molecular genetics of methylenetet rahydrofolate reductase deficiency. J\u00a0Inherit Metab Dis 1996;19:589\u201394. https:\/\/doi.org\/10.1007\/bf01799831.","DOI":"10.1007\/BF01799831"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_017","doi-asserted-by":"crossref","unstructured":"Goyette, P, Pai, A, Milos, R, Frosst, P, Tran, P, Chen, Z, et al.. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome 1998;9:652\u20136. https:\/\/doi.org\/10.1007\/s003359900838.","DOI":"10.1007\/s003359900838"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_018","doi-asserted-by":"crossref","unstructured":"van der Pol, KH, Nijenhuis, M, Soree, B, de Boer-Veger, NJ, Buunk, AM, Guchelaar, H, et al.. Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and allopurinol, and MTHFR, folic acid and methotrexate. Eur J Hum Genet 2024;32:155\u201362. https:\/\/doi.org\/10.1038\/s41431-022-01180-0.","DOI":"10.1038\/s41431-022-01180-0"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_019","doi-asserted-by":"crossref","unstructured":"Frosst, P, Blom, HJ, Milos, R, Goyette, P, Sheppard, CA, Matthews, RG, et al.. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111\u20133. https:\/\/doi.org\/10.1038\/ng0595-111.","DOI":"10.1038\/ng0595-111"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_020","doi-asserted-by":"crossref","unstructured":"Weisberg, I, Tran, P, Christensen, B, Sibani, S, Rozen, R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme ac tivity. Mol Genet Metabol 1998;64:169\u201372. https:\/\/doi.org\/10.1006\/mgme.1998.2714.","DOI":"10.1006\/mgme.1998.2714"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_021","doi-asserted-by":"crossref","unstructured":"Dervieux, T, Greenstein, N, Kremer, J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheuma toid arthritis. Arthritis Rheumatol 2006;54:3095\u2013103. https:\/\/doi.org\/10.1002\/art.22129.","DOI":"10.1002\/art.22129"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_022","doi-asserted-by":"crossref","unstructured":"van der Put, NM, Gabre\u00ebls, F, Stevens, EM, Smeitink, JA, Trijbels, FJ, Eskes, TK, et al.. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:044\u201351. https:\/\/doi.org\/10.1086\/301825.","DOI":"10.1086\/301825"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_023","unstructured":"Moscow, JA, Gong, M, He, R, Sgagias, MK, Dixon, KH, Anzick, SL, et al.. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55:3790\u20134."},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_024","doi-asserted-by":"crossref","unstructured":"Mutlak, QM, Kasim, AA. Impact of MTHFR gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients. Sci Rep 2024;14:15119. https:\/\/doi.org\/10.1038\/s41598-024-65199-7.","DOI":"10.1038\/s41598-024-65199-7"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_025","doi-asserted-by":"crossref","unstructured":"Ceballos, FC, Chamizo-Carmona, E, Mata-Mart\u00edn, C, Carrasco-Cubero, C, Aznar-S\u00e1nchez, JJ, Veroz-Gonz\u00e1lez, R, et al.. Pharmacogenetic sex-specific effects of methotrexate response in patients with rheumatoid arthritis. Pharmaceutics 2023;15:1661. https:\/\/doi.org\/10.3390\/pharmaceutics15061661.","DOI":"10.3390\/pharmaceutics15061661"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_026","doi-asserted-by":"crossref","unstructured":"Roszkiewicz, J, Micha\u0142ek, D, Ryk, A, Szmyd, B, Smolewska, E. The impact of single nucleotide polymorphisms in MTHFR and MTRR genes on disease activity and the presence of methotrexate treatment side effects in children with juvenile idiopathic arthritis. Arch Med Sci 2023;19:810\u201313. https:\/\/doi.org\/10.5114\/aoms\/163259.","DOI":"10.5114\/aoms\/163259"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_027","doi-asserted-by":"crossref","unstructured":"Eektimmerman, F, Swen, JJ, den Broeder, AA, Hazes, JMW, Kurreeman, FS, Verstappen, SMM, et al.. Genome-wide association study of methotrexate-induced liver injury in rheumatoid arthritis patients. Clin Pharmacol Ther 2023;113:916\u201323. https:\/\/doi.org\/10.1002\/cpt.2858.","DOI":"10.1002\/cpt.2858"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_028","doi-asserted-by":"crossref","unstructured":"Zhang, Q, Fu, P, Cao, Z, Huang, H, Wen, Q, Wang, K, et al.. MTHFR and MTRR genetic polymorphism of methotrexate therapy outcomes in early rheumatoid arthritis. Pharmgenomics Pers Med 2023;16:407\u201323. https:\/\/doi.org\/10.2147\/pgpm.s404949.","DOI":"10.2147\/PGPM.S404949"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_029","doi-asserted-by":"crossref","unstructured":"Zhu, J, Wang, Z, Tao, L, Han, L, Huang, Q, Fang, X, et al.. MTHFR gene polymorphism association with psoriatic arthritis risk and the efficacy and hepatotoxicity of methotrexate in psoriasis. Front Med 2022;9:869912. https:\/\/doi.org\/10.3389\/fmed.2022.869912.","DOI":"10.3389\/fmed.2022.869912"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_030","doi-asserted-by":"crossref","unstructured":"Kolan, SS, Li, G, Grimolizzi, F, Sexton, J, Goll, G, Kvien, TK, et al.. Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis. Front Pharmacol 2022;13:1075603. https:\/\/doi.org\/10.3389\/fphar.2022.1075603.","DOI":"10.3389\/fphar.2022.1075603"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_031","doi-asserted-by":"crossref","unstructured":"Londono, J, Saldarriaga, EL, Rueda, JC, Giraldo-Bustos, R, Angarita, JI, Restrepo, L, et al.. Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis. Biomed Rep 2020;13:34. https:\/\/doi.org\/10.3892\/br.2020.1341.","DOI":"10.3892\/br.2020.1341"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_032","doi-asserted-by":"crossref","unstructured":"Huang, J, Fan, H, Qiu, Q, Liu, K, Lv, S, Li, J, et al.. Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis. Ther Adv Chronic Dis 2020;11:2040622320916026. https:\/\/doi.org\/10.1177\/2040622320916026.","DOI":"10.1177\/2040622320916026"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_033","doi-asserted-by":"crossref","unstructured":"Sundbaum, JK, Baecklund, E, Eriksson, N, Hallberg, P, Kohnke, H, Wadelius, M. MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis. Pharmacogenomics 2020;21:337\u201346. https:\/\/doi.org\/10.2217\/pgs-2019-0186.","DOI":"10.2217\/pgs-2019-0186"},{"key":"2025122507573873958_j_dmpt-2025-0047_ref_034","doi-asserted-by":"crossref","unstructured":"The 1000 Genomes Project Consortium, Auton, A, Brooks, LD, Durbin, RM, Garrison, EP, Kang, HM, et al.. A global reference for human genetic variation. Nature 2015;526:6874. https:\/\/doi.org\/10.1038\/nature15393.","DOI":"10.1038\/nature15393"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0047\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0047\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T07:57:52Z","timestamp":1766649472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0047\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2025,12,25]]}},"alternative-id":["10.1515\/dmpt-2025-0047"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2025-0047","relation":{},"ISSN":["2363-8915"],"issn-type":[{"type":"electronic","value":"2363-8915"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}